Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood (2011) 118 (21): 813.

https://doi.org/10.1182/blood.V118.21.813.813

Published: 2011

Journal Articles

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Kyriakos P Papadopoulos, MD, Peter Lee, MD, PhD, Seema Singhal, MD, Joseph R. Holahan, MD, David H. Vesole, MD, PhD, Steven T. Rosen, MD, FRCPA, Lori Kunkel, MD, Alison L. Hannah, MD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 2930.

https://doi.org/10.1182/blood.V118.21.2930.2930

Published: 2011

Journal Articles

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

Anas Younes, MD, Francisco Hernandez, M.D., R. Gregory Bociek, MD, Yvette L. Kasamon, Peter Lee, MD, PhD, Lia Gore, MD, Amanda R Copeland, MSN, RN, CSN

Blood (2011) 118 (21): 2715.

https://doi.org/10.1182/blood.V118.21.2715.2715

Published: 2011

Journal Articles

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Anas Younes, MD, Francisco Hernandez, R. Gregory Bociek, MD, Yvette L. Kasamon, Peter Lee, MD, PhD, Lia Gore, MD, Daniela Buglio, MD, PhD, Amanda Copeland

Blood (2010) 116 (21): 3959.

https://doi.org/10.1182/blood.V116.21.3959.3959

Published: 2010

Journal Articles

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Andrzej J Jakubowiak, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Kevin T. McDonagh, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Andrew Belch, MD, Frederic J. Reu, MD, Nashat Y Gabrail, MD, Jeffrey Matous, MD, David H. Vesole, MD, PhD, Robert Z. Orlowski, MD, PhD, Mai H. Le, MD, Peter Lee, MD, PhD, Michael Wang, MD, The MMRC

Blood (2010) 116 (21): 1938.

https://doi.org/10.1182/blood.V116.21.1938.1938

Published: 2010

Journal Articles

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

Kyriakos Papadopoulos, MD, David Samuel diCapua Siegel, MD, PhD, Seema B. Singhal, MD, Jeffrey R. Infante, MD, Edward A. Sausville, MD, PhD, Michael S. Gordon, MD, Michael Kauffman, MD, PhD, Tina Woo, Susan Lee, Lynne Bui, MD, Alison L. Hannah, MD, Peter Lee, MD, PhD

Blood (2010) 116 (21): 3024.

https://doi.org/10.1182/blood.V116.21.3024.3024

Published: 2010

NARROW

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only